PHARMACOKINETICS OF INTRAVENOUS CEFOTAXIME IN CHILDREN

PHARMACOKINETICS OF INTRAVENOUS CEFOTAXIME IN CHILDREN - pharmacokineticx of intraveneus cefotaxime in children

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34521

Enrollment

Registered

2010-09-09

Start date

2010-12-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bacterial infectious diseases

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: 1. Patients who receive intravenous treatment with cefotaxime 2. Patients

Exclusion criteria

Exclusion criteria: Patients with a known allergy to cefotaxime or related compounds

Design outcomes

Primary

Measure	Time frame
The primary parameters in this study will be: * T1/2 (half-life during elimination phase) and Vss (volume of distribution in steady state) of cefotaxime and desacetyl-cefotaxime * Total body clearance, AUC (area under the time-concentration curve), MRT (mean residence time) Interpretation of pharmacokinetic parameters * Plasma concentrations and AUCs of cefotaxime will be compared to the MIC (minimal inhibitory concentration) of the microbe to be eliminated Cefotaxime/desacetyl-cefotaxime (cef/des ratio) ratios will be calculated to determine liver metabolism The T1/2 of cefotaxime and desacetyl-cefotaxime will be related to the GFR (glomerular filtration) * All pharmacokinetic parameters will be related to the personal characteristics of the subjects	—

Measure

Time frame

The primary parameters in this study will be: * T1/2 (half-life during elimination phase) and Vss (volume of distribution in steady state) of cefotaxime and desacetyl-cefotaxime * Total body clearance, AUC (area under the time-concentration curve), MRT (mean residence time) Interpretation of pharmacokinetic parameters * Plasma concentrations and AUC*s of cefotaxime will be compared to the MIC (minimal inhibitory concentration) of the microbe to be eliminated * Cefotaxime/desacetyl-cefotaxime (cef/des ratio) ratio*s will be calculated to determine liver metabolism * The T1/2 of cefotaxime and desacetyl-cefotaxime will be related to the GFR (glomerular filtration) * All pharmacokinetic parameters will be related to the personal characteristics of the subjects

—

Countries

Netherlands

Outcome results